期刊文献+

3D打印阴道模型塞应用在宫颈癌近距离治疗中的剂量学研究 被引量:8

Dosimetric study on 3D-printing multi-channel applicator interstitial brachytherapy for cervical cancer
在线阅读 下载PDF
导出
摘要 比较宫颈癌近距离治疗中肿块体积在50~90 cm^3之间,应用3D打印阴道模型塞插植治疗与常规三维腔内治疗的剂量学差异,研究3D打印阴道模型塞应用在大肿块宫颈癌近距离治疗中的可行性,为临床应用提供参考。收集甘肃省肿瘤医院放疗科2017年5月至2019年5月收治的宫颈癌患者行近距离放射治疗,肿块体积在50~90 cm^3之间的患者27例,其中14例患者在近距离治疗中行3D打印阴道模型塞插植治疗(3D printing interstitial BT,3DP-ISBT),另13例行常规三维腔内治疗(Intracavitary BT,ICBT)。在高危临床靶区(HR-CTV)处方剂量为6 Gy的情况下,评估HR-CTV体积大小,HR-CTV的D90(90%体积接收到的最低吸收剂量)、膀胱、直肠的剂量学差异。与ICBT组相比,3DP-ISBT组HR-CTV的体积及D90、直肠大于1 cm^3、2 cm^3、3 cm^3体积接收到的吸收剂量D1cc、D2cc和D3cc均无统计学差异(p>0.05)。膀胱的D1cc、D2cc和D3cc低于ICBT组,有统计学差异(p<0.05)。宫颈癌近距离治疗中肿块体积在50~90 cm3之间应用3DP-ISBT技术在剂量学上能够满足临床要求,与ICBT技术相比能更好地保护膀胱,在直肠的保护上未显示出优势。 In this study,we aimed to determine the dosimetric differences between 3D-printing multi-channel applicator interstitial brachytherapy(3DP-ISBT)and conventional three-dimensional intracavity treatment(ICBT)for cervical cancer with a high-risk clinical target volume(HR-CTV)of 50~90 cm3,to determine the feasibility of using 3DP-ISBT,and to provide a basis for the application of 3DP-ISBT in clinical practice.The study included 27 patients with cervical cancer and an HR-CTV of 50~90 cm3 who underwent radiotherapy at Gansu Provincial Cancer Hospital between May 2017 and May 2019.Among them,14 patients were treated with 3DP-ISBT and 13 were treated with ICBT.With a prescription dose was 6 Gy,evaluated the volume of the HR-CTV,the dosimetric differences in D90(received absorbed dose of 90%of the HR-CTV)of the HR-CTV,bladder,and rectum.Compared with the ICBT group,the 3DP-ISBT group showed no statistical differences in volume of the HR-CTV,D90 of the HR-CTV,and D1cc,D2cc,and D3cc of the rectum(doses received by 1 cm^3,2 cm^3,and 3 cm3 of the rectal volume)(p>0.05).D1cc,D2cc,and D3cc of the bladder were lower in the 3DP-ISBT group than in the ICBT group,and the difference was statistically significant(p<0.05).3DP-ISBT for cervical cancer with an HR-CTV volume of 50~90 cm3 can meet clinical requirements.The target can be irradiated with a sufficient dose in large-volume cancer and can protect the bladder better than can ICBT,however,there are no advantages in terms of protection of the rectum.
作者 陶娜 安永伟 欧阳水根 罗莉 孙晓燕 张春林 魏玺仪 TAO Na;AN Yongwei;OUYANG Shuigen;LUO Li;SUN Xiaoyan;ZHANG Chunlin;WEI Xiyi(Department of Radiotherapy,Gansu Provincial Cancer Hospital,Lanzhou 730050,China)
出处 《辐射研究与辐射工艺学报》 CAS CSCD 2020年第4期51-56,共6页 Journal of Radiation Research and Radiation Processing
关键词 宫颈癌 3D打印阴道模型塞 腔内治疗 剂量学 Cervical cancer 3D printing multi-channel applicator Intracavity treatment Dosimetry
  • 相关文献

参考文献6

二级参考文献44

  • 1Whitney CW,Sause W,Bundy BN,et al.Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage ⅡB-ⅣA carcinoma of the cervix with negative para-aortic lymph nodes:a gynecologic oncology group and southwest oncology group study[J].J Clin Oncol,1999,17:1339-1348.
  • 2Keys HM,Bundy BN,Stehman FB,et al.Cisplatin,radiation,and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ⅰ B cervical carcinoma[J].N Engl J Med,1999,340:1154-1161.
  • 3Peters WA 3rd,Liu PY,Barrett RJ.Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk earlystage cancer of the cervix[J].J Clin Oncol,2000,18:1606-1613.
  • 4Morris M,Eifel PJ,Lu J,et al.Pelvic radiation with concurrent chemotherapy compared with pelvic and pare-aortic radiation for high-risk cervical cancer[J].N Engl J Med,1999,340:1137-1143.
  • 5Rose PG,Bundy BN,Watkins EB,et al.Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer[J].N Engl J Med,1999,340:1144-1153.
  • 6Haie-Meder C,Potter R,Van Limbergen E,et al.Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (Ⅰ):concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J].Radiother Oncol,2005,74:235-245.
  • 7P(o)tter R,Haie-Meder C,Van Limbergen E,et al.Recommendations from gynaecological (GYN) GEC ESTRO working group (Ⅱ):concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy,radiation physics,radiobiology[J].Radiother Oncol,2006,78:67-77.
  • 8Hellebust TP,Kirisits C,Berger D,et al.Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group:considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy[J].Radiother Oncol,2010,96:153-160.
  • 9Dimopoulos JC,Petrow P,Tanderup K,et al.Recommendations from gynaecological (GYN) GEC-ESTRO working group (Ⅳ):basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy[J].Radiother Oncol,2012,103:113-122.
  • 10Nag S,Gupta N.A simple method of obtaining equivalent doses for use in HDR brachytherapy[J].Int J Radiat Oncol Biol Phys,2000,46:507-513.

共引文献86

同被引文献57

引证文献8

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部